More recently, drug-eluting stents (DESs) have emerged as the predominant percutaneous strategy in patients with coronary artery disease. This Review summarizes the knowledge on coronary stenting ...

Xience V™ everolimus-eluting stent (EES ... randomized 2300 patients with symptomatic coronary artery disease (CAD) to receive the Resolute stent (1150) or EES (1150). At the 12-month follow ...

Conclusion: The sirolimus-eluting coronary stent is associated with less ISR than non-drug-containing stents, but further investigation is needed to determine its exact place in the treatment of ...

Global Drug-Eluting Stents Market is valued at approximately USD 7.37 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6.6% over the forecast period 2023-2030.

The global interventional cardiology devices market is on a strong growth trajectory, with a projected Compound Annual Growth ...

Singh, A. , Sinha, R. , Saran, M. , Kazmi, D. , Gupta, H. and Seth, G. (2025) Efficacy and Safety of Dual Antiplatelet Therapy in High-Risk, Post-Percutaneous Coronary Intervention Patients beyond One ...

Implantable Drug Eluting Devices Market. The Global Implantable Drug Eluting Devices Market was valued at approximately USD ...

Biotronik today announced a strategic shift that includes the divestiture of its Vascular Intervention (VI) business to ...

Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced it has entered into a definitive agreement to acquire substantially all of the Vascular ...

Teleflex has announced a plan to split its business into two separate independent companies—and it’s setting up one of its ...